| Literature DB >> 31402893 |
Carmen Fiuza-Luces1, Pedro L Valenzuela2, Sara Laine-Menéndez1, Miguel Fernández-de la Torre1, Verónica Bermejo-Gómez1, Laura Rufián-Vázquez1, Joaquín Arenas1,3, Miguel A Martín1,3, Alejandro Lucia4,5, María Morán1,3.
Abstract
Purpose: Mitochondrial diseases (MD) are among the most prevalent neuromuscular disorders. Unfortunately, no curative treatment is yet available. This study analyzed the effects of exercise training in an animal model of respiratory chain complex I deficiency, the Harlequin (Hq) mouse, which replicates the clinical features of this condition.Entities:
Keywords: AIF deficiency; OXPHOS; harlequin mutant mouse; mitochondrial diseases; rare diseases; resistance training; respiratory chain complex I
Year: 2019 PMID: 31402893 PMCID: PMC6673140 DOI: 10.3389/fneur.2019.00790
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Representation of mice baseline evaluation before group assignment.
Figure 2Representation of the study design.
Effects of the exercise intervention on study endpoints with repeated measurements before and after the intervention.
| Aerobic fitness (distance, in m) | Control | 10 | 191 ± 40 | 158 ± 37 | 0.372 | 0.256 | |
| Strength (forelimb test, g) | Control | 11 | 109 ± 9 | 111 ± 8 | 0.537 | ||
| Balance (time to fall, in s) | Control | 11 | 59 ± 12 | 23 ± 7 | 0.073 | 0.544 | |
| Serum CK (U/L) | Control | 11 | 93 ± 14 | 96 ± 8 | 0.976 | 0.499 | 0.290 |
Data are mean ± standard error of the mean. Significant p-values (<0.05) are highlighted in bold. CK, creatinekinase.
p = 0.016 for pre vs. post;
p = 0.003 for pre vs.post.
Biochemical variables in Hq mice.
| Anabolism protein levels in | P70S6K | 10/9 | 168 ± 20 | 292 ± 16 | |
| pP70S6K | 10/9 | 156 ± 30 | 249 ± 30 | ||
| pP70S6K/P70S6K | 10/9 | 91 ± 3 | 109 ± 6 | 0.095 | |
| Mt biogenesis protein levels in | PGC-1α | 5/4 | 82 ± 7 | 126 ± 19 | |
| TFAM | 11/10 | 83 ± 3 | 94 ± 4 | 0.060 | |
| OXPHOS activities in | Complex I | 10/9 | 75 ± 4 | 95 ± 6 | |
| Complex II | 10/9 | 82 ± 5 | 94 ± 5 | 0.161 | |
| Complex III | 1109 | 79 ± 5 | 97 ± 4 | ||
| Complex IV | 10/9 | 88 ± 4 | 102 ± 4 | 0.136 | |
| Complex V | 10/9 | 77 ± 9 | 105 ± 9 | ||
| Citrate synthase | 10/8 | 79 ± 3 | 91 ± 4 | 0.059 | |
| OXPHOS protein levels in | ATP5a | 11/9 | 86 ± 12 | 98 ± 13 | 0.387 |
| UQCRC2 | 11/9 | 77 ± 9 | 91 ± 21 | 0.705 | |
| MTCO1 | 11/9 | 76 ± 13 | 108 ± 25 | 0.529 | |
| SDHB | 11/9 | 86 ± 5 | 85 ± 4 | 0.468 | |
| NDUFB8 | 11/9 | 77 ± 6 | 81 ± 10 | 0.809 | |
| NDUFS1 | 10/8 | 85 ± 5 | 93 ± 5 | 0.095 | |
| Citrate synthase | 11/9 | 84 ± 4 | 124 ± 14 | 0.132 | |
| OXPHOS activities in | Complex I | 10/5 | 87 ± 12 | 93 ± 19 | 0.953 |
| Complex II | 5/5 | 89 ± 12 | 70 ± 7 | 0.548 | |
| Complex III | 5/5 | 117 ± 16 | 86 ± 14 | 0.310 | |
| Complex IV | 4/5 | 104 ± 7 | 99 ± 8 | 0.811 | |
| Citrate synthase | 5/5 | 118 ± 10 | 117 ± 17 | 0.905 | |
| OXPHOS protein levels in | ATP5a | 4/5 | 108 ± 14 | 125 ± 20 | 0.343 |
| UQCRC2 | 4/5 | 123 ± 12 | 146 ± 14 | 0.486 | |
| MTCO1 | 4/5 | 118 ± 4 | 119 ± 8 | 0.886 | |
| SDHB | 4/5 | 99 ± 2 | 94 ± 10 | 1.00 | |
| NDUFB8 | 4/5 | 79 ± 9 | 74 ± 10 | 0.886 | |
| NDUFS1 | 4/5 | 30 ± 3 | 21 ± 6 | 0.343 | |
| Antioxidant enzymes protein levels in | mtSOD | 11/10 | 94 ± 13 | 94 ± 5 | 0.607 |
| cSOD | 11/10 | 120 ± 20 | 97 ± 10 | 0.557 | |
| GR | 11/10 | 99 ± 4 | 109 ± 7 | 0.512 | |
| CAT | 11/10 | 204 ± 22 | 141 ± 23 |
Data (mean ± SEM) are expressed and analyzed as a percentage of mean value of an age- and gender-matched matched non-exercised wild type (WT) group (n = 4–12). Significant p-values are highlighted in bold. ATP5A, ATP synthase alpha subunit; CAT, catalase; cSOD, cytosolic superoxide dismutase; GR, glutathione reductase; Mt, mitochondrial; MTCO1, mitochondrial cytochrome c oxidase subunit I; mtSOD, mitochondrial superoxide dismutase; NDUFB8, ubiquinone oxidoreductase subunit B8; NDUFS1, ubiquinone oxidoreductase subunit S1; P70S6K, total ribosomal protein S6 kinase beta-1; pP70S6K, ribosomal protein S6 kinase beta-1 phosphorylated at threonine 389; PGC-1α, proliferator activated receptor gamma co-activator 1α; SDHB, succinate dehydrogenase complex iron sulfur subunit B; TFAM, transcription factor A mitochondrial; UQCRC2, ubiquinol-cytochrome C reductase core protein 2.